Position in RPRX
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$2,904,103
+$419,938 QoQ
Shares Held
60,540
-5.8% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Metis Global Partners, LLC holds $14,162,320 across 8 Biotechnology names. RPRX ranks #3 (20.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
11,667 | $5,209,782 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,448 | $3,436,702 | |
| 3 | RPRX |
Royalty Pharma plc
This page
|
60,540 | $2,904,103 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
4,049 | $1,339,692 | |
| 5 | INCY |
Incyte Corp
|
4,723 | $444,528 | |
| 6 | INSM |
INSMED Inc
|
2,041 | $333,744 | |
| 7 | MRNA |
Moderna, Inc.
|
6,542 | $332,333 | |
| 8 | PBYI |
Puma Biotechnology, Inc.
|
25,264 | $161,436 |
All Filings in RPRX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,904,103 | 60,540 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $2,484,165 | 64,290 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $2,301,526 | 65,236 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $2,445,716 | 67,880 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $1,149,350 | 36,921 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $914,814 | 35,861 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $614,939 | 21,737 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $517,142 | 19,611 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $411,392 | 13,546 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $375,479 | 13,367 | Shares | Sole | 2024-02-06 | |
| No filing history on record for this holder in this stock. | ||||||